ACE and type 1 diabetes mellitus: The Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects (ATLANTIS) study used ramipril versus placebo in 140 people with type 1 diabetes and microalbuminuria and normotension, and it showed regression to normoalbuminuria in 20% of the ramipril-treated group, compared with 4% of the placebo-treated group [55].